Previous work in experimental models and tumor cell lines suggested that an MMR-deficient profile could be a predictive factor for a poor response to chemotherapeutics, i.e., cisplatin, carboplatin, and methylating agents, at variance with the efficacy of immunotherapy in CRC with MMR/MSI deficiency [43]. The gene discussed is MRC1; the disease is colorectal carcinoma.